OBJECTIVE: The purpose of this study was to assess the prevalence of pelvic floor disorders and sexual function in survivors of gynecologic cancer. STUDY DESIGN: We surveyed survivors of gynecologic cancer (survivors) and women seeking gynecologic care (control patients) who were >30 years old. All survivors were disease- and treatment-free for ≥1 year. Validated questionnaires were used to evaluate pelvic floor disorders. RESULTS: One hundred eight control patient and 260 survivor questionnaires were completed. A high prevalence of pelvic floor disorders was observed in both groups; 56% of control subjects and 70% of survivors reported moderate to severe urinary incontinence (P > .05). Survivors were more likely to experience fecal incontinence (42% vs 32%; P = .02). Survivors reported less sexual desire (P = .04) and less ability to climax (P = .04), despite no difference in dyspareunia. CONCLUSION: Fecal incontinence and sexual dysfunction are significant problems in survivors of gynecologic cancer.
OBJECTIVE: The purpose of this study was to assess the prevalence of pelvic floor disorders and sexual function in survivors of gynecologic cancer. STUDY DESIGN: We surveyed survivors of gynecologic cancer (survivors) and women seeking gynecologic care (control patients) who were >30 years old. All survivors were disease- and treatment-free for ≥1 year. Validated questionnaires were used to evaluate pelvic floor disorders. RESULTS: One hundred eight control patient and 260 survivor questionnaires were completed. A high prevalence of pelvic floor disorders was observed in both groups; 56% of control subjects and 70% of survivors reported moderate to severe urinary incontinence (P > .05). Survivors were more likely to experience fecal incontinence (42% vs 32%; P = .02). Survivors reported less sexual desire (P = .04) and less ability to climax (P = .04), despite no difference in dyspareunia. CONCLUSION:Fecal incontinence and sexual dysfunction are significant problems in survivors of gynecologic cancer.
Authors: P G Rose; B N Bundy; E B Watkins; J T Thigpen; G Deppe; M A Maiman; D L Clarke-Pearson; S Insalaco Journal: N Engl J Med Date: 1999-04-15 Impact factor: 91.245
Authors: Lari Wenzel; Israel DeAlba; Rana Habbal; Brenda Coffey Kluhsman; Diane Fairclough; Linda U Krebs; Hoda Anton-Culver; Ross Berkowitz; Noreen Aziz Journal: Gynecol Oncol Date: 2005-05 Impact factor: 5.482
Authors: Emily S Lukacz; Jean M Lawrence; J Galen Buckwalter; Raoul J Burchette; Charles W Nager; Karl M Luber Journal: Int Urogynecol J Pelvic Floor Dysfunct Date: 2005-04-26
Authors: Ingrid Nygaard; Matthew D Barber; Kathryn L Burgio; Kimberly Kenton; Susan Meikle; Joseph Schaffer; Cathie Spino; William E Whitehead; Jennifer Wu; Debra J Brody Journal: JAMA Date: 2008-09-17 Impact factor: 56.272
Authors: C Emi Bretschneider; Kemi M Doll; Jeannette T Bensen; Paola A Gehrig; Jennifer M Wu; Elizabeth J Geller Journal: Int Urogynecol J Date: 2016-02-12 Impact factor: 2.894
Authors: Aparna S Ramaseshan; Jessica Felton; Dana Roque; Gautam Rao; Andrea G Shipper; Tatiana V D Sanses Journal: Int Urogynecol J Date: 2017-09-19 Impact factor: 2.894
Authors: Helena C Frawley; Kuan-Yin Lin; Catherine L Granger; Rosemary Higgins; Michael Butler; Linda Denehy Journal: Support Care Cancer Date: 2019-06-27 Impact factor: 3.603
Authors: Christelle Schofield; Robert U Newton; Paul A Cohen; Daniel A Galvão; Joanne A McVeigh; Ganendra R Mohan; Jason Tan; Stuart G Salfinger; Leon M Straker; Carolyn J Peddle-McIntyre Journal: Support Care Cancer Date: 2018-02-01 Impact factor: 3.603
Authors: Ingrid E Nygaard; Ali Wolpern; Tyler Bardsley; Marlene J Egger; Janet M Shaw Journal: Am J Obstet Gynecol Date: 2020-08-14 Impact factor: 8.661